RFA-HL-26-016-Full-Announcement.html

This document is a Request for Application (RFA) for the federal grant opportunity titled "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)". The goal of this initiative is to support the development and validation of transformative, multi-use platforms or technologies that can enable and accelerate advancements in the areas of early detection, screening, model development, clinical diagnosis, treatment, control, behavior, prevention, or epidemiology related to heart, lung, blood, and sleep (HLBS) diseases and disorders.

Eligible applicant types include public and private organizations, such as universities, non-profits, for-profit companies, and small businesses. The funding will be provided through grants under CFDA numbers 93.838 (Lung Diseases Research), 93.837 (Cardiovascular Diseases Research), 93.839 (Blood Diseases and Resources Research), and 93.233 (National Center on Sleep Disorders Research) programs. The federal agency administering this grant opportunity is the Department of Health and Human Services, National Institutes of Health.